Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ziopharm Takes Bigger Loss as Research Costs Grow

By Pharmaceutical Processing | March 19, 2013

NEW YORK (AP) — Drug developer Ziopharm Oncology Inc. said Monday it took a larger loss in the fourth quarter as its research and development expenses nearly tripled.

During the fourth quarter Ziopharm said it started treating patients in a midstage clinical trial of a therapy that is designed to use the immune system to fight cancer. Once treatment began, the company issued 3.6 million shares of stock to Intrexon Corp., its partner on the drug. Ziopharm took a charge of $18.7 million as a result.

Including that charge Ziopharm said its research and development costs climbed to $35 million from $12.7 million a year ago. The company took a loss of $30.2 million, or 37 cents per share, in the fourth quarter. Ziopharm said its loss totaled 48 cents per share if one-time gains and charges are excluded. It lost $13.2 million, or 19 cents per share, in the fourth quarter of 2011. Revenue was unchanged at $200,000.

Analysts were expecting a loss of 28 cents per share and $200,000 in revenue, according to FactSet.

Before the end of March Ziopharm plans to report data from a late-stage clinical trial of its drug palifosfamide as a treatment for soft tissue sarcoma. It is enrolling patients in another late-stage trial evaluating the drug as a lung cancer treatment, and recently started a mid-stage trial of the drug as a treatment for testicular and ovarian cancer. It does not have any products on the market.

Ziopharm says palifosfamide is designed to stop tumor growth by binding to the DNA of cancer cells and interfering with DNA function. Ziopharm’s Picasso trial is intended to evaluate palifosfamide and a chemotherapy drug as primary treatment for soft tissue sarcoma that has metastasized. The company says it will report results from the study during the last week of March.

The other late-stage trial, Matisse, evaluates palifosfamide as part of a regimen for metastatic small cell lung cancer in patients who have not been treated with chemotherapy.

Palifosfamide is given intravenously, but Ziopharm said it is also studying a capsule version.

The company reported a loss of $96.1 million, or $1.22, in 2012 after losing $63.8 million, or 97 cents per share, in 2011. Revenue rose to $800,000 from $667,000.

Ziopharm Oncology shares picked up 10 cents to $5.71 Monday and fell 2 cents to $5.69 in aftermarket trading.

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE